Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic
Huadong Medicine Co., Ltd (SHE: 000963) announced that the U.S. Food and Drug Administration (FDA) has...
Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination
Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that the U.S. Food and Drug Administration (FDA) has granted...
Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy
Fresenius Kabi and TQ Therapeutics announced a strategic‑development agreement granting Fresenius Kabi exclusive rights to...
BMS’s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase III Study
Bristol‑Myers Squibb (BMS, NYSE: BMY) announced positive topline results from the Phase 3 SCOUT‑HCM study evaluating mavacamten...
WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development
WuXi Biologics (HKG: 2269) announced a licensing agreement granting Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) global exclusive...
ABM Therapeutics Licenses MEK1/2 Inhibitor ABM‑168 to Mosaica Medicines for Global Development
ABM Therapeutics Inc. announced a licensing agreement granting Mosaica Medicines global rights to ABM‑168, an...
WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership
WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA, announced its...
Fosun Kairos Secures Greater China Rights to ElpasBio’s AlloJoin for Knee Osteoarthritis
Fosun Kairos, a joint venture between Fosun Pharmaceutical (SHA: 600196, HKG: 2196) and Gilead Sciences/Kite...
Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB 1.2 B, Adding siRNA Platform for Chronic Diseases
Sino Biopharmaceutical Ltd. (HKG: 1177) announced it has agreed to acquire a 100 % equity stake in...
NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation
China’s National Healthcare Security Administration (NHSA) this week released the Series of Guidelines for Real‑World...
J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma
Johnson & Johnson (J&J, NYSE: JNJ) announced positive topline results from the Phase 3 MajesTEC‑9 study of...
Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
Immvira Bioscience Inc. filed for an initial public offering on the Hong Kong Stock Exchange...
Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
Exegenesis Bio Inc., a gene therapy developer founded in 2019, filed for a listing on...
Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced the launch of an AI-powered R&D platform focused...
QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
Jiangsu QYuns Therapeutics Co., Ltd. (HKG: 2509) announced that its US partner Caldera Therapeutics, Inc. has...
Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that the U.S. Food and Drug Administration (FDA)...
WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities
WuXi Biologics (HKG: 2269) announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has...
NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development
NVIDIA Corporation and Eli Lilly and Company (NYSE: LLY) announced a first‑of‑its‑kind AI co‑innovation lab to...
AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D
AstraZeneca plc (AZ, NASDAQ: AZN) announced the acquisition of Modella AI, a leader in artificial intelligence...
Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
Xellsmart, a Suzhou‑based stem‑cell startup, announced the completion of RMB 400 million (USD 57.3 million) in combined Series B/B+...